New drugs contribute to AbbVie's upbeat 2020 view; shares hit year-high
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Abbvie (ABBV) PT Raised to $97 at Piper Sandler
February 7, 2020 1:23 PM ESTPiper Sandler analyst Christopher Raymond raised the price target on Abbvie (NYSE: ABBV) to $97.00 (from $95.00) while maintaining a Overweight rating following results.
... MoreAbbVie (ABBV) Sees Strong Gains Post-EPS
February 7, 2020 12:39 PM ESTAbbVie (NYSE: ABBV) seeing strong gains following results this morning. Shares up 5.5%.
... More